Biological
GSK257049 clinical trials
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
7 studies that test it; most in 2006 (2)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2011 | 1 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Engerix-B (1) · Fanasil, pyrimethamine drug combination (1) · Amodiaquine (1)
Studies
Open first, then newest update. How each study uses GSK257049 is read from its arms, and is right about nine times in ten.
Testing it · 7
- Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian InfantsCompletedPhase 2GlaxoSmithKlineNCT00289185Written as RTS,S/AS02D
- A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.CompletedPhase 1GlaxoSmithKlineNCT00197067Written as RTS,S/AS02D and RTS,S/AS02A
- Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve AdultsCompletedPhase 2GlaxoSmithKlineNCT01857869Written as GSK257049 Dosage 1
- Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African InfantsCompletedPhase 2GlaxoSmithKlineNCT01231503Written as GSK Biological's Investigational Malaria Vaccine 257049
- Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.CompletedPhase 2GlaxoSmithKlineNCT00380393Written as GSK malaria vaccine 257049 Vaccine
- Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian ChildrenCompletedPhase 2GlaxoSmithKlineNCT00360230Written as GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
- Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 VaccineCompletedPhase 2GlaxoSmithKlineNCT00323622Written as GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049